MYCRONIC AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 376.9 SEK | -1.28% |
|
+3.53% | +32.57% |
| Apr. 25 | Mycronic AB has Received Replacement Order for A Prexision 80 Evo from an Existing Customer in Asia | CI |
| Apr. 18 | Transcript : Mycronic AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 23.98 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Semiconductor Equipment & Testing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +32.57% | 3.4B | B- | ||
| +25.66% | 360B | B | ||
| +18.14% | 121B | B | ||
| +35.54% | 101B | B+ | ||
| +10.67% | 19.99B | C+ | ||
| +5.56% | 18.87B | B+ | ||
| +35.96% | 9.77B | B+ | ||
| +24.11% | 9.34B | B | ||
| -7.97% | 7.54B | C+ | ||
| -23.57% | 6.08B | D+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MYCR Stock
- Ratings Mycronic AB
